Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of subcutaneous vedolizumab in ulcerative colitis and Crohn's disease
NL-OMON55460Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (3 arms), sponsored by Takeda. Primary endpoint: Subject-year-adjusted treatment-emergent adverse events and serious adverse events. Started Jun 2017; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON55460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55460.